Abbott Laboratories (ABT) : Founders Financial Securities added new position in Abbott Laboratories during the most recent quarter end. The investment management firm now holds 85,752 shares of Abbott Laboratories which is valued at $3,722,494 , the company said in a statement filed on Apr 11, 2016 with the SEC.Abbott Laboratories makes up approximately 1.73% of Founders Financial Securities’s portfolio.
Abbott Laboratories closed down -0.1 points or -0.23% at $43.41 with 36,20,361 shares getting traded on Friday. Post opening the session at $43.53, the shares hit an intraday low of $43.18 and an intraday high of $43.548 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Peachtree Investment Advisors sold out all of its stake in ABT during the most recent quarter. The investment firm sold 5,036 shares of ABT which is valued $218,613.British Columbia Investment Management Corp boosted its stake in ABT in the latest quarter, The investment management firm added 20,637 additional shares and now holds a total of 676,587 shares of Abbott Laboratories which is valued at $28,741,416. Abbott Laboratories makes up approx 0.27% of British Columbia Investment Management Corp’s portfolio.Trust Co Of Virginia Va reduced its stake in ABT by selling 1,323 shares or 3.37% in the most recent quarter. The Hedge Fund company now holds 37,970 shares of ABT which is valued at $1,612,966. Abbott Laboratories makes up approx 0.29% of Trust Co Of Virginia Va’s portfolio.Kistler-tiffany Companies reduced its stake in ABT by selling 95 shares or 1.28% in the most recent quarter. The Hedge Fund company now holds 7,310 shares of ABT which is valued at $310,529. Abbott Laboratories makes up approx 0.17% of Kistler-tiffany Companies’s portfolio.Curbstone Financial Management Corp reduced its stake in ABT by selling 2,800 shares or 10.4% in the most recent quarter. The Hedge Fund company now holds 24,112 shares of ABT which is valued at $1,024,278. Abbott Laboratories makes up approx 0.35% of Curbstone Financial Management Corp’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.61. The company had revenue of $5188.00 million for the quarter, compared to analysts expectations of $5254.57 million. The company’s revenue was down -3.1 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.71 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .Shares were Reiterated by RBC Capital Mkts on Jan 29, 2016 to “Outperform” and Lowered the Price Target to $ 45 from a previous price target of $51 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.